Dr Qianxin Wu

Staff Scientist

Qianxin is a staff scientist jointly between Gene Editing R&D team and Cellular Genetics. She is passionate about developing gene editing and single cell based biotechnologies and ultimately to use these tools to answer the fundamental question of gene regulation.

Qianxin joined Sanger Human Genome Editing R&D team since 2017. She became a joint member between Human Genome Editing R&D team and Cellular Genetics in 2022. Currently, she is leading two projects on the following two areas:

  1. Create a novel biotechnology for personalised CRISPR screens. (Sanger translational grant)
  2. Develop sequencing method directly linking genotype to phenotype at single cell level using microfluidic platform. (Industry grant with ACXEL)

At Sanger, Qianxin developed dead Cas9-based epigenetic modification systems (dCas9-EM) and used of thousands of uniquely inserted DNA barcodes to unbiasedly analyse context dependent dCas9-EM effects in human iPSCs and iNeurons. Her research deciphered the rules underling CRISPR activation.

During COVID-19 pandemic, she developed INSIGHT technology in order to provide a combined point-of-care and centralised sequencing based testing solution.

Prior to Sanger, Qianxin was a postdoc in Professor Tudor Fulga’s lab, Weatherall Institute, Oxford University. During her postdoc work, she has developed a genome engineering discovery platform, namely GenERA, enabling a systems-level functional characterisation of primary RNA regulatory networks.

Qianxin completed her Phd under supervision of Professor Nigel Gooderham at Imperial College London. During her PhD, she studied how a strong metabolic perturbation could change the entire metabolic network in a mouse model and whether gene expression controlled by microRNAs could explain these changes.

My timeline


My publications

Loading publications...